ReviewFrontiers in oncology2025
Evaluation of the safety and efficacy of surgery for radio-recurrent prostate cancer: a systematic review and meta-analysis.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surgery plays a critical role in managing radio-recurrent prostate cancer (PCa). This study aims to comprehensively review its effectiveness and associated severe complications. Methods: A thorough review of PubMed and EMBASE databases up to July 2024 was conducted, focusing on recurrence-free survival (RFS) with salvage surgery across various subgroups. Severe complications were also assessed using the Clavien-Dindo Scale (CDS). Survival curves were reconstructed using WebPlotDigitizer and a newly developed shiny application. Results: Forty-four studies were included, with 17 papers (2056 patients) contributing to survival curve reconstruction. Among 1654 patients treated with salvage surgery after eliminating duplicate cases, the median RFS was 63.9 months, with 2-, 3-, and 5-year rates of 65.6%, 59.3%, and 51.2%, respectively. Factors associated with better RFS included robot-assisted surgery [hazard ratio (HR):1.49, p < 0.001], lower rates of seminal vesicle invasion (SVI) (HR: 0.75, p = 0.006) and lymph node involvement (LNI) (HR: 0.74, p = 0.006), higher proportion of adjuvant androgen deprivation therapy (ADT) (HR: 2.96, p < 0.001), and higher values of pathological Gleason scores (GS) (≤7/≥8) (HR:1.30, p < 0.001). Severe complications (grade ≥ IIIa) occurred in 404 out of 2537 patients (15.9%, 95% CI: 14.5 to 17.4). Conclusions: This study comprehensively assesses complications and conducts a pooled analysis of RFS for salvage surgery in radio-recurrent PCa. Robot-assisted surgery, lower rates of SVI and LNI, adjuvant ADT, and higher proportions of pathological GS ≤7 appear promising as prognostic factors for RFS. However, confirming these findings will necessitate randomized controlled trials due to low levels of evidence and study heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.